Compare Kinross Gold Corporation (KGC) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinross Gold Corporation vs Health Care Select Sector SPDR Fund — how do they compare? Kinross Gold Corporation trades at $23.74 (market cap $27.62B), while Health Care Select Sector SPDR Fund trades at $170.81 (market cap $43.48B). The key difference: Health Care Select Sector SPDR Fund is the larger of the two by market cap, and Kinross Gold Corporation pays a 0.69% dividend while Health Care Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kinross Gold Corporation for 53 Days and Health Care Select Sector SPDR Fund for 100 Days on average.
| KGC | XLV | |
|---|---|---|
Market Cap | $27.62B | $43.48B |
Volume | 6,347,266 | 11,121,431 |
Sector | Basic Materials | — |
52-Week High | $38.06 | $175.68 |
52-Week Low | $22.47 | $141.95 |
Typical Hold Time | 53 Days | 100 Days |
Enterprise Value | $25.70B | — |
Dividend Yield | 0.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinross Gold Corporation (KGC) trades at $23.34, up 0.69% today, with strong fundamentals including a P/E of 8.87 and robust profitability metrics. Recent earnings have consistently beaten expectations, though technical indicators signal bearish momentum. The company reported $7.05B revenue and $2.39B net income for 2025, with cash flow from operations reaching $3.76B. However, production guidance cuts for 2026-2027 have pressured the stock, offset by increased shareholder returns targeting 50% of free cash flow.
KGC presents a mixed outlook: attractive valuation and earnings growth support upside to the $38.80 consensus price target, but near-term risks include operational setbacks at key mines and ongoing legal investigations. The stock's bearish technical trend and rising costs warrant caution, though institutional buying and high analyst buy ratings (58.63%) indicate underlying confidence in long-term value.
XLV trades at $168.16, down 0.39% with a bearish technical signal from moving averages. The healthcare ETF maintains strong cost advantages with a 0.08% expense ratio compared to peers. Recent news highlights XLV's defensive positioning during market volatility and its historical outperformance during Fed rate hikes. Technical indicators show RSI levels in neutral territory while ADX signals selling pressure.
XLV offers diversified healthcare exposure with competitive expense ratios, positioning it well for defensive investing. Key risks include political uncertainty around healthcare policy and concentrated exposure to domestic S&P 500 stocks. The ETF's low-cost structure and sector diversification provide stability amid market volatility, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
